Alteration in the plasma concentration of a DAAO inhibitor, 3-methylpyrazole-5-carboxylic acid, in the ketamine-treated rats and the inuence on the pharmacokinetics of plasma D-tryptophan

Proceedings of the Japan Academy Series B: Physical and Biological Sciences

Volumn 87, Issue 10, 2011, Pages 641-648

  Haruta, Naomi ^a   Iizuka, Hideaki ^a   Ishii, Kana ^a   Yoshihara, Shunsuke ^a   Ichiba, Hideaki ^a   Fukushima, Takeshi ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

3 methylpyrazole 5 carboxylic acid; D amino acid oxidase; D tryptophan; Inhibitor; Ketamine; Rat

Indexed keywords

5 METHYL 3 PYRAZOLECARBOXYLIC ACID; 5-METHYLPYRAZOLE-3-CARBOXYLIC ACID; DEXTRO AMINO ACID OXIDASE; ENZYME INHIBITOR; KETAMINE; PYRAZOLE DERIVATIVE; TRYPTOPHAN;

ANIMAL; ARTICLE; BLOOD; DRUG ANTAGONISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; RAT; REPRODUCIBILITY; SPRAGUE DAWLEY RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; D-AMINO-ACID OXIDASE; ENZYME INHIBITORS; KETAMINE; MALE; MASS SPECTROMETRY; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; TRYPTOPHAN;

RATTUS;

EID: 84855676909     PISSN: 03862208     EISSN: 13492896     Source Type: Journal    
DOI: 10.2183/pjab.87.641     Document Type: Article

References (25)

1. Freedman, R. (2003) Schizophrenia. N. Engl. J. Med. 349, 1738-1749.
2. Coyle, J.T. (1996) The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry 3, 241-253.
3. Javitt, D.C. and Zukin, S.R. (1991) Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301-1308.
4. Carpenter, W.T. Jr. and Buchanan, R.W. (1994) Schizophrenia. N. Engl. J. Med. 330, 681-690.
5. Schell, M.J., Molliver, M.E. and Snyder, S.H. (1995) D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc. Natl. Acad. Sci. U.S.A. 92, 3948-3952.
6. Tsai, G.C., Yang, P.C., Chung, L.C., Lange, N. and Coyle, J.T. (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44, 1081-1089.
7. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B. Jr. and Charney, D.S. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214.
8. Noda, Y., Yamada, K., Furukawa, H. and Nabeshima, T. (1995) Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine-a new model of schizophrenia. Br. J. Pharmacol. 116, 2531-2537.
9. Becker, A., Peters, B., Schroeder, H., Mann, T., Huether, G. and Grecksch, G. (2003) Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 687-700.
10. Watanabe, M., Yoshikawa, M., Takeyama, K., Hashimoto, A., Kobayashi, H. and Suzuki, T. (2010) Subchronic administration of ketamine decreases the mRNA expression of serine racemase in rat brain. Tokai J. Exp. Clin. Med. 35, 137-143.
11. Takeyama, K., Yoshikawa, M., Oka, T., Kawaguchi, M., Suzuki, T. and Hashimoto, A. (2006) Ketamine enhances the expression of serine racemase and D-amino acid oxidase mRNAs in rat brain. Eur. J. Pharmacol. 540,82-86.
12. Madeira, C., Freitas, M.E., Vargas-Lopes, C., Wolosker, H. and Panizzutti, R. (2008) Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr. Res. 101,76-83.
13. Molla, G., Sacchi, S., Bernasconi, M., Pilone, M.S., Fukui, K. and Pollegioni, L. (2006) Characterization of human D-amino acid oxidase. FEBS Lett. 580, 2358-2364.
14. Smith, S.M., Uslaner, J.M. and Hutson, P.H. (2010) The therapeutic potential of D-amino acid oxidase (DAAO) inhibitors. Open Med. Chem. J. 4,3-9.
15. Duplantier, A.J., Becker, S.L., Bohanon, M.J., Borzilleri, K.A., Chrunyk, B.A., Downs, J.T., Hu, L.Y., EI-Kattan, A., James, L.C., Liu, S.P., Lu, J.M., Maklad, N., Mansour, M.N., Mente, S., Piotrowski, M.A., Sakya, S.M., Sheehan, S., Steyn, S.J., Strick, C.A., Williams, V.A. and Zhang, L. (2009) Discovery, SAR, and pharmaco-kinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors. J. Med. Chem. 52, 3576-3585.
16. Adage, T., Trillat, A.C., Quattropani, A., Perrin, D., Cavarec, L., Shaw, J., Guerassimenko, O., Giachetti, C., Greco, B., Chumakov, I., Halazy, S., Roach, A. and Zaratin, P. (2008) In vitro and in vivo pharmacological profile of AS057278, a selective D-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur. Neuropsychopharmacol. 18, 200-214.
17. Iizuka, H., Ishii, K., Hirasa, Y., Kubo, K. and Fukushima, T. (2011) Fluorescence determination of D-and L-tryptophan concentrations in rat plasma following administration of tryptophan enantiomers using HPLC with pre-column derivatization. J. Chromatogr. B Analyst. Technol. Biomed. Life Sci. 879, 3208-3213.
18. Ishii, K., Ogaya, T., Song, Z., Iizuka, H. and Fukushima, T. (2010) Changes in the plasma concentrations of D-kynurenine and kynurenic acid in rats after intraperitoneal administration of tryptophan enantiomers. Chirality 22, 901-906.
19. Fukushima, T., Sone, Y., Mitsuhashi, S., Tomiya, M. and Toyo'oka, T. (2009) Alteration of kynurenic acid concentration in rat plasma following optically pure kynurenine administration: A comparative study between enantiomers. Chirality 21, 468-472.
20. Ogaya, T., Song, Z., Ishii, K. and Fukushima, T. (2010) Changes in extracellular kynurenic acid concentrations in rat prefrontal cortex after D-kynurenine infusion: An in vivo microdialysis study. Neurochem. Res. 35, 559-563.
21. Yao, C.H., Qi, L., Qiao, J.A., Zhang, H.Z., Wang, F.Y., Chen, Y. and Yang, G.L. (2010) High-performance affinity monolith chromatography for chiral separation and determination of enzyme kinetic constants. Talanta 82, 1332-1337.
22. Edwards, S.R. and Mather, L.E. (2001) Tissue uptake of ketamine and norketamineenantiomers in the rat. Indirect evidence for extrahepatic metabolic inversion. Life Sci. 69, 2051-2066.
23. Williams, M.L., Mager, D.E., Parenteau, H., Girish, G., Timothy, S.T., Mike, M. and Irving, W.W. (2004) Effects of protein calorie malnutrition on the pharmacokinetics of ketamine in rats. Drug Metab. Dispos. 32, 786-793.
24. Bernstein, H.G., Becker, A., Keilhoff, G., Spilker, C., Gorczyca, W.A., Braunewell, K.H. and Grecksch, G. (2003) Brain region-specific changes in the expression of calcium sensor proteins after repeated applications of ketamine to rats. Neurosci. Lett. 339,95-98.
25. Keilhoff, G., Becker, A., Grecksch, G., Wolf, G. and Bernstein, H.G. (2004) Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience 126, 591-598.